Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 14/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14992309 | 0.92 | EGLN1 (0.41) | EGLN1MAPTMAPK1HTTNPSR1 | |
| SCHEMBL14992943 | 0.89 | EGLN1 (0.44) | EGLN1MAPTMAPK1HTTNPSR1 | |
| SCHEMBL14992929 | 0.88 | EGLN1 (0.42) | EGLN1ADORA2A | |
| SCHEMBL16626265 | 0.84 | EGLN1 (0.52) | EGLN1MAPTMAPK1HTTNPSR1 | |
| SCHEMBL14992371 | 0.83 | EGLN1 (0.49) | EGLN1MAPTMAPK1HTTNPSR1 | |
| SCHEMBL622759 | 0.81 | EGLN1 (0.67) | EGLN1 | |
| SCHEMBL14992287 | 0.79 | EGLN1 (0.48) | EGLN1MAPTMAPK1HTTNPSR1 | |
| SCHEMBL15899579 | 0.79 | EGLN1 (0.51) | EGLN1 | |
| SCHEMBL627589 | 0.78 | EGLN1 (0.47) | EGLN1L3MBTL1ADORA2A | |
| SCHEMBL14992445 | 0.77 | EGLN1 (0.48) | EGLN1MAPK1ADORA2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10246442-B2 | 4-Aminoquinazolin compounds as prolyl hydroxylase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2019-04-02 | — | — | US | disclosed |
| US-20180148435-A9 | 4-AMINOQUINAZOLIN COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-31 | — | — | US | disclosed |
| US-20170320859-A1 | 4-AMINOQUINAZOLIN COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-11-09 | — | — | US | disclosed |
| US-9573940-B2 | 4-aminoquinazolinyl-2-yl-1-pyrazole-4-carboxylic acid compounds as prolyl hydroxylase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2017-02-21 | — | — | US | disclosed |
| US-20150197507-A1 | 4-Aminoquinazolinyl compounds as prolyl hydroxylase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2015-07-16 | — | — | US | disclosed |
| US-20140309215-A1 | 4-AMINOQUINAZOLIN-2-YL-1-PYRRAZOLE-4-CARBOXYLIC ACID COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARAMCEUTICA NV (BE) | 2014-10-16 | — | — | US | disclosed |
| US-8796263-B2 | 4-aminoquinazolin-2-yl-1-pyrrazole-4-carboxylic acid compounds as prolyl hydroxylase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2014-08-05 | — | — | US | disclosed |
| US-20130143871-A1 | 4-AMINOQUINAZOLIN-2-YL-1-PYRRAZOLE-4-CARBOXYLIC ACID COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2013-06-06 | — | — | US | disclosed |
| CN-103068821-A | 4 - aminoquinazolin- 2 - yl - 1 - pyrrazole - 4 - carboxylic acid compounds as prolyl hydroxylase inhibitors | JANSSEN PHARMACEUTICA NV | 2013-04-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170320859-A1 | 4-AMINOQUINAZOLIN COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS | P4HA1, EGLN3, EGLN2 | EGLN1 6/4885MAPT 4353/4885MAPK1 2002/4885 |
| US-20180148435-A9 | 4-AMINOQUINAZOLIN COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS | P4HA1, EGLN3, EGLN2 | EGLN1 6/4885MAPT 4353/4885MAPK1 2002/4885 |
| US-20140309215-A1 | 4-AMINOQUINAZOLIN-2-YL-1-PYRRAZOLE-4-CARBOXYLIC ACID COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS | P4HA1, PAH, EGLN3 | EGLN1 7/4885MAPT 4451/4885MAPK1 1621/4885 |
| US-20150197507-A1 | 4-Aminoquinazolinyl compounds as prolyl hydroxylase inhibitors | P4HA1, EGLN3, EGLN2 | EGLN1 6/4885MAPT 4370/4885MAPK1 2038/4885 |
| US-10246442-B2 | 4-Aminoquinazolin compounds as prolyl hydroxylase inhibitors | P4HA1, EGLN3, EGLN2 | EGLN1 6/4885MAPT 4353/4885MAPK1 2002/4885 |
| US-20130143871-A1 | 4-AMINOQUINAZOLIN-2-YL-1-PYRRAZOLE-4-CARBOXYLIC ACID COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS | P4HA1, PAH, EGLN3 | EGLN1 7/4885MAPT 4451/4885MAPK1 1621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.